Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw founded Biocon in 1978, in the garage of her rented house in Bengaluru. She built it into India’s first biotech company to go public, and became the country’s first self-made woman billionaire. She is widely seen as the founder of India’s biotechnology industry.

mcqquestion.com

Indian Economy · IndEco0143

Kiran Mazumdar-Shaw

Founder of India’s biotech industry

1978

Founds Biocon in her rented Bengaluru garage, aged 25, with ₹10,000 in capital.

1979

Biocon becomes the first Indian company to export enzymes to the US and Europe.

2004

Biocon’s IPO makes it the first Indian biotech company to go public, oversubscribed 33x.

Dec 2025

Biocon consolidates Biocon Biologics into a wholly-owned subsidiary, in a $5.5 billion deal.

From garage enzymes to global biosimilars

India’s first self-made woman billionaire built an industry from scratch — starting with industrial enzymes, and ending with biosimilar versions of the world’s most complex biologic drugs.

mcqquestion.com · Indian Economy ⬇ Download as image

Must Know

• Kiran Mazumdar-Shaw was born on 23 March 1953, in Bangalore (then in Mysore State).
• She earned a Bachelor’s degree in zoology, with honours, from Bangalore University in 1973.
• She then trained as a master brewer, earning a postgraduate diploma in malting and brewing from Ballarat College, Melbourne, in 1975.
• In 1978, at age 25, she founded Biocon in the garage of her rented house in Bengaluru, with just ₹10,000 in capital.
• Biocon initially made industrial enzymes. In 1979, it became the first Indian company to export enzymes to the United States and Europe.
• In 2004, Biocon went public. It was the first Indian biotech company to have an IPO, oversubscribed 33 times.
• Biocon also developed India’s first human insulin, moving the company from enzymes into biopharmaceuticals.
• She became India’s first self-made woman billionaire, largely on the strength of Biocon’s growth.

Good to Know

• Kiran Mazumdar-Shaw faced open gender discrimination in Biocon’s early years. Investors hesitated, and some vendors refused to deal with her unless she hired a male manager.
• She struggled to find staff willing to work for a woman-led company, in India’s business environment of the late 1970s.
• Biocon later expanded into biosimilars: more affordable versions of complex biologic drugs, made from living cells rather than chemical synthesis.
• Its biosimilars now include affordable versions of major global drugs, including treatments originally sold as Humira, Herceptin, and Stelara.
• She received the Padma Shri in 1989 and the Padma Bhushan in 2005, India’s fourth- and third-highest civilian awards.
• She also holds the Othmer Gold Medal for contributions to science and chemistry, and France’s Chevalier de l’Ordre National de la Légion d’Honneur (2016). In 2020, she received Australia’s Order of Australia, for strengthening India-Australia ties.
• Biocon Biologics is Biocon’s separate subsidiary that runs its biosimilars business specifically.

Test Yourself

Please wait…

1. At what age did Kiran Mazumdar-Shaw found Biocon, and in which year?

22, in 1975

30, in 1983

25, in 1978

28, in 1981

 Loading…

 

Great to Know

• Kiran Mazumdar-Shaw’s career traces the arc of India’s own biotech industry: from basic enzyme manufacturing in the 1970s to complex biosimilar drugs today.
• Biocon’s 2004 listing helped establish that an Indian company could build and sell advanced biopharmaceutical science, not just manufacture generic small-molecule drugs cheaply.
• Her early struggle to be taken seriously as a woman entrepreneur is often cited as a landmark case in Indian business. This came well before “women in STEM” became a mainstream policy conversation.
• Biocon’s shift toward biosimilars reflects a wider global trend. As patents on expensive biologic drugs expire, companies race to make cheaper, chemically-similar versions available to more patients.

Current Affairs

• On 6 December 2025, Biocon Limited announced it will make Biocon Biologics a wholly-owned subsidiary again. The deal values the biosimilars unit at $5.5 billion. (Source: Business Standard, 6 Dec 2025)
• The deal has two parts. Biocon will buy out minority investors (Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP) through a share swap. (Source: Pearce IP, 6 Dec 2025)
• Separately, Biocon will buy out Viatris (formerly Mylan)’s residual stake for $815 million, partly funded through a $500 million share placement. (Source: Forbes, 8 Dec 2025)
• The consolidation is expected to complete by 31 March 2026, bringing Biocon’s generics and biosimilars businesses under one roof. It strengthens Biocon’s position in diabetes, oncology, and immunology drugs. (Source: Bloomberg, 6 Dec 2025)